Let’s face it: Cloud-based High-Performance Computing (HPC) offers unprecedented computational power. These systems can perform quadrillions of calculations per second. But that computational horsepower comes at a price – not just financially, but in the form of a steep learning curve and a constant battle against configuration headaches, unpredictable costs, and delays. For researchers working… The post How Fovus enabled a biotech to accelerate high-throughput screening by up to 96x with cloud HPC appeared first on Drug Discovery and Development ..read more

Real-world evidence and real-world data The use of real-world evidence (RWE) to support regulatory and reimbursement decision-making received increasing attention over the past decades. The US FDA provides a definition of RWE as “the clinical evidence about the usage and potential benefits and risks of a medical product”1. RWE can be used across the entire… The post The future of RWD and RWE in healthcare decision-making: Applications of novel real-world data collection methods for healthcare decision-making appeared first on Drug Discovery and Development ..read more

 “Nearly all diseases stem from a molecular mechanism going wrong,” writes Sergei Yakneen, chief technology officer of Alphabet’s Isomorphic Labs in a recent blog post. “Whether it’s an infectious agent disrupting our cellular machinery or a breakdown in processes like DNA repair, identifying the right protein and finding molecules to interact with it is… The post The latest on Isomorphic Labs’ plans to use AI models to revamp drug discovery appeared first on Drug Discovery and Development ..read more

Boston-based DeepCure may be an AI-focused biotech, but it sets itself apart by focusing its AI-powered platform on historically challenging drug targets that have eluded traditional approaches. “While AI in drug discovery is often viewed as a means to accelerate and reduce costs, our focus at DeepCure is on achieving true novelty in drug development… The post How DeepCure taps reinforcement learning for first-in-class therapies appeared first on Drug Discovery and Development ..read more

Redwood City, California–based Earli is, in many ways, a quintessential Silicon Valley startup. As is often the case, there’s not only a Stanford connection but a grand ambition. The company is developing a “synthetic biopsy” platform that aims to detect cancer at its earliest stages by programming cancer cells to reveal themselves and even self-destruct.… The post Earli and Accenture partner in quest to turn cancer against itself appeared first on Drug Discovery and Development ..read more

Imagine going from near-total blindness to seeing the world in a whole new light – literally. That’s the reality for some participants in a recent gene therapy trial for LCA1, where vision improvements ranged from a 100-fold increase to a 10,000-fold jump. LCA1 (Leber Congenital Amaurosis 1) is a type of Leber Congenital Amaurosis that… The post Gene therapy yields 100x vision average improvement, with a few reaching 10,000x appeared first on Drug Discovery and Development ..read more

By Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the functional capacity of many adults worldwide; it is one of the most significant considerations when designing combination devices. Ergonomic Combination Devices for Arthritis Patients Arthritis significantly impacts how people grasp and manipulate objects, reducing their… The post Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic Hands appeared first on Drug Discovery and Development ..read more

 “Nearly all diseases stem from a molecular mechanism going wrong,” writes Sergei Yakneen, chief technology officer of Alphabet’s Isomorphic Labs in a recent blog post. “Whether it’s an infectious agent disrupting our cellular machinery or a breakdown in processes like DNA repair, identifying the right protein and finding molecules to interact with it is… The post The latest on Isomophic Labs’ plans to use AI models to revamp drug discovery appeared first on Drug Discovery and Development ..read more

Google Cloud’s Shweta Maniar is on a mission to revamp drug discovery with the power of generative AI, the trendy type of AI that can create new content. The tech is well-suited for a range of applications in drug discovery and across the life sciences. Whether it’s supporting organizations in their drug discovery efforts or… The post From Bayer’s regulatory streamlining to Superluminal’s protein modeling, Google Cloud’s AI gaining biotech momentum appeared first on Drug Discovery and Development ..read more

GLP-1 therapies just got a whole lot less expensive for patients who pay out of pocket. Eli Lilly’s Zepbound (tirzepatide) single-dose vials are now available at rates similar to compounded versions of semaglutide. Patients can now access a four-week supply of Zepbound for as little as $399 for the 2.5 mg dose and $549 for… The post Lilly shakes up obesity drug market with Zepbound self-pay price now up to 70% lower than the competition appeared first on Drug Discovery and Development ..read more